Ivermectin for preventing and treating COVID-19-Reference-Cited by-同舟云学术

Ivermectin for preventing and treating COVID-19

Published:2022-06-21 Issue:6 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Popp Maria¹,Reis Stefanie¹,Schießer Selina¹,Hausinger Renate Ilona²,Stegemann Miriam³,Metzendorf Maria-Inti⁴,Kranke Peter¹,Meybohm Patrick¹,Skoetz Nicole⁵,Weibel Stephanie¹

Affiliation:

1. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Wuerzburg; Wuerzburg Germany

2. Department of Nephrology, Klinikum Rechts der Isar; Technical University of Munich; Munich Germany

3. Department of Infectious Diseases and Respiratory Medicine; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Germany

4. Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Duesseldorf; Duesseldorf Germany

5. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference284 articles.

1. Randomized, double-blind, multi centre phase II, proof of concept, dose finding clinical trial on ivermectin for the early treatment of COVID-19 clinicaltrialsregister.eu/ctr-search/trial/2020-002283-32/IT

2. Buonfrate D Chesini F Martini D Roncaglioni MC Ojeda Fernandez ML Alvisi MF High dose ivermectin for the early treatment of COVID-19 (COVER Study): a randomised, bouble-blind, multicentre, phase II, dose-finding, proof of concept clinical trial papers.ssrn.com/sol3/papers.cfm?abstract_id=3918289 10.2139/ssrn.3918289

3. Buonfrate D Chesini F Martini D Roncaglioni MC Ojeda Fernandez ML Alvisi MF High dose ivermectin for the early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial International Journal of Antimicrobial Agents 106516 10.1016/j.ijantimicag.2021.106516

4. COVidIVERmectin: ivermectin for treatment of Covid-19 (COVER) clinicaltrials.gov/ct2/show/NCT04438850

5. Chaccour C Casellas A Blanco-Di Matteo A Pineda I Fernandez-Montero A Ruiz-Castillo P The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial researchsquare.com/article/rs-116547/v1 10.21203/rs.3.rs-116547/v1

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity;Heliyon;2024-08

2. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants;International Journal of Antimicrobial Agents;2024-08

3. Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial;BMC Infectious Diseases;2024-07-22

4. Risk factors associated with severe COVID-19 outcomes in Jamaica: a cross-sectional study of national surveillance data;Revista Panamericana de Salud Pública;2024-04-04

5. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes;Journal of Infection;2024-04